KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.

Angela Dispenzieri, Efstathios Kastritis, Ashutosh D Wechalekar, Stefan O Schönland, Kihyun Kim, Vaishali Sanchorawala, Heather J Landau, Fiona Kwok, Kenshi Suzuki, Raymond L Comenzo, Deborah Berg, Guohui Liu, Arun Kumar, Douglas V Faller, Giampaolo Merlini

Leukemia 36(1) 225-235

PMID34168284
PMCIDPMC8727292
DOI10.1038/s41375-021-01317-y
发表日期2021-06-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1-2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85) or physician's choice (dexamethasone ± melphalan, cyclophosphamide, thalidomide, or lenalidomide; n = 83) in 28-day cycles until progression or toxicity. Primary endpoints were hematologic response rate and 2-year vital organ deterioration or mortality rate. Only the first primary endpoint was formally tested at this interim analysis. Best hematologic response rate was 53% with ixazomib-dexamethasone vs 51% with physician's choice (p = 0.76). Complete response rate was 26 vs 18% (p = 0.22). Median time to vital organ deterioration or mortality was 34.8 vs 26.1 months (hazard ratio 0.53; 95% CI, 0.32-0.87; p = 0.01). Median treatment duration was 11.7 vs 5.0 months. Adverse events of clinical importance included diarrhea (34 vs 30%), rash (33 vs 20%), cardiac arrhythmias (26 vs 15%), nausea (24 vs 14%). Despite not meeting the first primary endpoint, all time-to-event data favored ixazomib-dexamethasone. These results are clinically relevant to this relapsed/refractory patient population with no approved treatment options.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。